Preventing hepatitis C patients from being lost in the health-care system

December 18, 2014

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care.

Despite efforts to manage HCV, it is one of the most prevalent diseases with up to 150 million individuals worldwide living with chronic infection according to the World Health Organization (WHO). In the U.S. about 3.2 million people are infected with HCV, making it the main cause of chronic hepatitis disease. Up to 70% of those with acute infection have no symptoms and are typically unaware they have HCV until years later after the disease has progressed to cirrhosis, liver cancer (hepatocellular carcinoma [HCC]), or liver failure.

Medical evidence emphasizes HCV screening of at-risk individuals such as injection drug users, blood transfusion recipients, children born to mothers with chronic infection, or adults born between 1945 and 1965 in order to improve diagnosis of the disease. Yet some programs are not comprehensive and one prior study estimates that 50% to 75% of chronic HCV patients remain unaware of their infection.

"The inadequacy of screening programs has made it difficult for state health departments to accurately determine the extent of HCV and the rate of transmission within the community," explains Kendra Viner, Ph.D., MPH, from the Philadelphia Department of Public Health. "Our study examines the management of HCV care at a population level to determine which patients tend to fall out of the medical system and why this might occur."

The present study uses the Philadelphia Department of Public Health's hepatitis surveillance data, which includes individuals who have a first positive HCV test reported to the department from January 2010 through December 2013. Population estimates were calculated using the 2010 U.S. Census along with the National Health and Nutrition Examination Survey (NHANES) data and accounts for high risk groups (homeless, incarcerated) who were not represented in NHANES estimates.

Results show that based on estimates from NHANES and high risk populations, 2.9% of the 1,584,848 Philadelphia residents were estimated to be positive for HCV. During the study time frame, the Philadelphia Department of Public Health received positive HCV test results from 13,596 individuals, with 1,745 (27%) of these individuals in care and 956 (15%) having been treated or receiving treatment.

"Our findings show that many HCV patients are lost at each stage of the health care continuum from screening to disease confirmation to care and treatment," concludes Dr. Viner. "The fact that so few patients with HCV are making it to treatment underscores the need to build awareness among at-risk groups of the importance of screening and continued care. It is critical that public health officials and clinicians understand why patients are lost at each stage so that changes can be made to improve care for those with chronic HCV."
-end-
This study was funded by a cooperative agreement (1U51PS004045-01) between The Centers of Disease Control and Prevention and the Philadelphia Department of Public Health for viral hepatitis surveillance and epidemiologic studies.

Access the full study on the Wiley Press Room here. This study is published in Hepatology. Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com.

Full citation:"The Continuum of Hepatitis C Testing and Care." Kendra Viner, Danica Kuncio, E. Claire Newbern and Caroline C. Johnson. Hepatology; (DOI: 10.1002/hep.27584)

URL: http://doi.wiley.com/10.1002/hep.27584

Author Contact: Media wishing to speak with Dr. Viner may contact Jeff Moran 215-688-5244.

About the Journal

Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.

About Wiley

Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content.

Wiley

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.